Thiabendazole; Pesticide Tolerances, 65289-65296 [2016-21753]
Download as PDF
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
BILLING CODE 6560–50–P
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 81
[EPA–HQ–OAR–2012–0918; FRL–9951–91–
OAR]
Air Quality Designations for the 2012
Primary Annual Fine Particle (PM2.5)
National Ambient Air Quality Standard
(NAAQS) for Areas in Georgia and
Florida
Correction
In rule document 2016–21338
beginning on page 61136 in the issue of
Tuesday, September 6, 2016, make the
following correction:
§ 83.311
[Amended]
On page 61141, in § 81.311, in the
table, in the third column, the sixth
entry should read ‘‘Unclassifiable/
Attainment’’.
■
[FR Doc. C1–2016–21338 Filed 9–21–16; 8:45 am]
BILLING CODE 1505–01–D
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 180
[EPA–HQ–OPP–2015–0554; FRL–9950–05]
I. General Information
Thiabendazole; Pesticide Tolerances
Environmental Protection
Agency (EPA).
ACTION: Final rule.
AGENCY:
This regulation establishes
tolerances for residues of thiabendazole
in or on the legume vegetable group 6
and foliage of legume vegetable group 7.
Syngenta Crop Protection requested
these tolerances under the Federal Food,
Drug, and Cosmetic Act (FFDCA). This
regulation also assigns an expiration
date to existing tolerances for bean, dry,
seed at 0.1 part per million (ppm) and
soybean at 0.1 ppm as well as removes
a threshold of regulation determination
for seed treatment use of thiabendazole
on dry pea (including field pea, pigeon
pea, chickpea or lentil). Lastly, this
regulation establishes a time-limited
tolerance on sweet potato. The timelimited tolerance is in response to EPA’s
granting of an emergency exemption
under the Federal Insecticide,
Fungicide, and Rodenticide Act
(FIFRA). The time-limited tolerance will
expire and be revoked on December 31,
2019.
ehiers on DSK5VPTVN1PROD with RULES
SUMMARY:
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
This regulation is effective
September 22, 2016. Objections and
requests for hearings must be received
on or before November 21, 2016, and
must be filed in accordance with the
instructions provided in 40 CFR part
178 (see also Unit I.C. of the
SUPPLEMENTARY INFORMATION).
ADDRESSES: The docket for this action,
identified by docket identification (ID)
number EPA–HQ–OPP–2015–0554, is
available at https://www.regulations.gov
or at the Office of Pesticide Programs
Regulatory Public Docket (OPP Docket)
in the Environmental Protection Agency
Docket Center (EPA/DC), West William
Jefferson Clinton Bldg., Rm. 3334, 1301
Constitution Ave. NW., Washington, DC
20460–0001. The Public Reading Room
is open from 8:30 a.m. to 4:30 p.m.,
Monday through Friday, excluding legal
holidays. The telephone number for the
Public Reading Room is (202) 566–1744,
and the telephone number for the OPP
Docket is (703) 305–5805. Please review
the visitor instructions and additional
information about the docket available
at https://www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT:
Michael Goodis, Registration Division
(7505P), Office of Pesticide Programs,
Environmental Protection Agency, 1200
Pennsylvania Ave. NW., Washington,
DC 20460–0001; main telephone
number: (703) 305–7090; email address:
RDFRNotices@epa.gov.
SUPPLEMENTARY INFORMATION:
DATES:
[FR Doc. 2016–22760 Filed 9–21–16; 8:45 am]
A. Does this action apply to me?
You may be potentially affected by
this action if you are an agricultural
producer, food manufacturer, or
pesticide manufacturer. The following
list of North American Industrial
Classification System (NAICS) codes is
not intended to be exhaustive, but rather
provides a guide to help readers
determine whether this document
applies to them. Potentially affected
entities may include:
• Crop production (NAICS code 111).
• Animal production (NAICS code
112).
• Food manufacturing (NAICS code
311).
• Pesticide manufacturing (NAICS
code 32532).
B. How can I get electronic access to
other related information?
You may access a frequently updated
electronic version of EPA’s tolerance
regulations at 40 CFR part 180 through
the Government Printing Office’s e-CFR
site at https://www.ecfr.gov/cgi-bin/textidx?&c=ecfr&tpl=/ecfrbrowse/Title40/
40tab_02.tpl.
PO 00000
Frm 00025
Fmt 4700
Sfmt 4700
65289
C. How can I file an objection or hearing
request?
Under FFDCA section 408(g), 21
U.S.C. 346a, any person may file an
objection to any aspect of this regulation
and may also request a hearing on those
objections. You must file your objection
or request a hearing on this regulation
in accordance with the instructions
provided in 40 CFR part 178. To ensure
proper receipt by EPA, you must
identify docket ID number EPA–HQ–
OPP–2015–0554 in the subject line on
the first page of your submission. All
objections and requests for a hearing
must be in writing, and must be
received by the Hearing Clerk on or
before November 21, 2016. Addresses
for mail and hand delivery of objections
and hearing requests are provided in 40
CFR 178.25(b).
In addition to filing an objection or
hearing request with the Hearing Clerk
as described in 40 CFR part 178, please
submit a copy of the filing (excluding
any Confidential Business Information
(CBI)) for inclusion in the public docket.
Information not marked confidential
pursuant to 40 CFR part 2 may be
disclosed publicly by EPA without prior
notice. Submit the non-CBI copy of your
objection or hearing request, identified
by docket ID number EPA–HQ–OPP–
2015–0554, by one of the following
methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the online
instructions for submitting comments.
Do not submit electronically any
information you consider to be CBI or
other information whose disclosure is
restricted by statute.
• Mail: OPP Docket, Environmental
Protection Agency Docket Center (EPA/
DC), (28221T), 1200 Pennsylvania Ave.
NW., Washington, DC 20460–0001.
• Hand Delivery: To make special
arrangements for hand delivery or
delivery of boxed information, please
follow the instructions at https://
www.epa.gov/dockets/contacts.html.
Additional instructions on
commenting or visiting the docket,
along with more information about
dockets generally, is available at https://
www.epa.gov/dockets.
II. Summary of Agency’s Action
A. Petitioned-For Tolerances
In the Federal Register of September
9, 2015 (80 FR 54257) (FRL–9933–26),
EPA issued a document pursuant to
FFDCA section 408(d)(3), 21 U.S.C.
346a(d)(3), announcing the filing of a
pesticide petition (PP 5F8368) by
Syngenta Crop Protection, LLC, P.O.
Box 18300, Greensboro, NC 27419. The
petition requested that 40 CFR 180.242
E:\FR\FM\22SER1.SGM
22SER1
65290
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
be amended by establishing tolerances
for residues of the fungicide
thiabendazole in or on legume
vegetables (succulent or dried), crop
group 6 at 0.01 parts per million (ppm);
foliage of legume vegetables, crop group
7, except pea, field, hay and vines at
0.01 ppm; pea, field, hay at 0.15 ppm;
and pea, field, vines at 0.03 ppm. The
petition also requested to amend the
tolerances in 40 CFR 180.242 for
residues of thiabendazole by removing
the tolerances in or on bean, dry, seed
at 0.1 ppm and soybean at 0.1 ppm.
That document referenced a summary of
the petition prepared by Syngenta, the
registrant, which is available in the
docket, https://www.regulations.gov. A
comment was received on the notice of
filing. EPA’s response to this comment
is discussed in Unit IV.C.
Based upon review of the data
supporting the petition, EPA has
modified levels at which the tolerances
are being established by this document.
The reason for these changes are
explained in Unit IV.D.
ehiers on DSK5VPTVN1PROD with RULES
B. Thiabendazole Threshold of
Regulation Determination
In 2008, EPA established a rule
codifying its determination that the use
of thiabendazole as a seed treatment for
dry pea using a maximum application
rate of 0.075 pound of active ingredient
per 100 pounds of seed did not require
a tolerance because residues were below
the Agency’s threshold of regulation. (73
FR 1976 (Jan. 11, 2008); see 40 CFR
180.2010). The new tolerances for
residues of thiabendazole on crop group
6 legume vegetable commodities,
including dry pea, and on crop group 7,
foliage of legume vegetable
commodities, which includes vines and
hay from the legume vegetables that the
Agency is establishing make the existing
threshold of regulation determination
unnecessary. The new tolerances cover
residues on these commodities resulting
from new seed treatment uses that allow
for higher application rates and thus
residues associated uses covered by the
threshold of regulation determination
are covered by the new tolerances. As a
result, the Agency is removing this
determination from section 180.2010.
C. Tolerance for Use of Pesticide Under
Emergency Exemption
In response to a crisis exemption
request and authorization of a specific
exemption request filed under section
18 of the Federal Insecticide, Fungicide,
and Rodenticide Act (FIFRA) on behalf
of the North Carolina Department of
Agriculture and Consumer Services for
the emergency use of thiabendazole to
control black rot disease on sweet
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
potato, EPA is establishing pursuant to
FFDCA section 408(l)(6) time-limited
tolerances for the use of thiabendazole
on sweet potato at 10 ppm with an
expiration date of December 31, 2019.
As part of its evaluation of the
emergency exemption application, EPA
assessed the potential risks presented by
residues of thiabendazole on sweet
potato. In doing so, EPA considered the
safety standard in section 408(b)(2) of
FFDCA, and the Agency decided that
the necessary tolerance under section
408(l)(6) of FFDCA would be consistent
with the safety standard and with
FIFRA section 18. Consistent with the
need to move quickly on the emergency
exemption in order to address an urgent
non-routine situation and to ensure that
the resulting food is safe and lawful,
EPA is issuing this tolerance without
notice and opportunity for public
comment as provided in section
408(l)(6) of FFDCA. Although this timelimited tolerance expires and is revoked
on December 31, 2019, under section
408(l)(5) of FFDCA, residues of the
pesticide not in excess of the amounts
specified in the tolerance remaining in
or on sweet potato after that date will
not be unlawful, provided the pesticide
was applied in a manner that was lawful
under FIFRA, and the residues do not
exceed a level that was authorized by
the time-limited tolerance at the time of
that application. EPA will take action to
revoke this time-limited tolerance
earlier if any experience with, scientific
data on, or other relevant information
on this pesticide indicate that the
residues are not safe.
Because this time-limited tolerance is
being approved under emergency
conditions, EPA has not made any
decisions whether thiabendazole meets
FIFRA’s registration requirements for
use in or on sweet potato or whether a
permanent tolerance for this use would
be appropriate. Under these
circumstances, EPA does not believe
that this time-limited tolerances serves
as a basis for registration of
thiabendazole by a State for Special
Local Needs under FIFRA section 24(c).
Nor does this tolerance serve as the
basis for persons in any State other than
North Carolina to use this pesticide on
sweet potato under FIFRA section 18
absent the issuance of an emergency
exemption applicable within that State.
For additional information regarding the
emergency exemption for thiabendazole,
contact the Agency’s Registration
Division at the address provided under
FOR FURTHER INFORMATION CONTACT.
PO 00000
Frm 00026
Fmt 4700
Sfmt 4700
III. Aggregate Risk Assessment and
Determination of Safety
Section 408(b)(2)(A)(i) of FFDCA
allows EPA to establish a tolerance (the
legal limit for a pesticide chemical
residue in or on a food) only if EPA
determines that the tolerance is ‘‘safe.’’
Section 408(b)(2)(A)(ii) of FFDCA
defines ‘‘safe’’ to mean that ‘‘there is a
reasonable certainty that no harm will
result from aggregate exposure to the
pesticide chemical residue, including
all anticipated dietary exposures and all
other exposures for which there is
reliable information.’’ This assessment
includes exposure through drinking
water and in residential settings, but
does not include occupational exposure.
Section 408(b)(2)(C) of FFDCA requires
EPA to give special consideration to
exposure of infants and children to the
pesticide chemical residue in
establishing a tolerance and to ‘‘ensure
that there is a reasonable certainty that
no harm will result to infants and
children from aggregate exposure to the
pesticide chemical residue . . . .’’
Consistent with FFDCA section
408(b)(2)(D), and the factors specified in
FFDCA section 408(b)(2)(D), EPA has
reviewed the available scientific data
and other relevant information in
support of this action. EPA has
sufficient data to assess the hazards of
and to make a determination on
aggregate exposure for thiabendazole
including exposure resulting from the
tolerances, including the time-limited
tolerance, established by this action.
EPA’s assessment of exposures and risks
associated with thiabendazole follows.
A. Toxicological Profile
EPA has evaluated the available
toxicity data and considered its validity,
completeness, and reliability as well as
the relationship of the results of the
studies to human risk. EPA has also
considered available information
concerning the variability of the
sensitivities of major identifiable
subgroups of consumers, including
infants and children.
The thyroid and liver (centrilobular
hypertrophy) are the primary target
organs of thiabendazole toxicity.
Thiabendazole produced a treatment
related increase in absolute and relative
liver weights in both sexes in a chronic
dog study. Other treatment related
effects reported were histopathological
changes in kidneys (hyperplasia of
transitional epithelium, tubular
degeneration) and spleen (congested
and pigmented) in rats. Additional toxic
effects observed in these studies
included decreases in body weight and/
or food consumption. The available
E:\FR\FM\22SER1.SGM
22SER1
ehiers on DSK5VPTVN1PROD with RULES
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
database indicates that thiabendazole is
not neurotoxic. In an acute
neurotoxicity rat study (ACN), decreases
in the Functional Observation Battery
(FOB) (reduced body temperature in
males, reduced rearing in females, and
reduced locomotor activity in males and
females at time of peak effect
(approximately 3 hours post-dose)) were
seen without morphological or
histopathological effects on the brain.
Thiabendazole was not neurotoxic in
rats in a subchronic neurotoxicity study.
In a 21-day dermal toxicity study in rats,
no systemic or dermal effects were seen
at the limit dose (1,000 milligram/
kilogram/day (mg/kg/day)). In prenatal
developmental toxicity studies in rats,
rabbits, and mice and in the 2generation reproduction study in rats,
effects in the fetuses or neonates
occurred at or above doses that caused
maternal or parental toxicity.
In the adult animal, effects on the
thyroid following thiabendazole
exposure were observed at a dose lower
than the neurotoxicity dose observed in
the ACN. There are no thiabendazole
data with which to determine whether
this is also the case in the fetus/
postnatal animal. Based on a weight of
evidence (WOE) approach considering
all the available hazard and exposure
information for thiabendazole, the
Agency concluded that a developmental
thyroid toxicity study is required since
there is clear evidence of thyroid
toxicity in adult animals and thus a
concern for potential toxicity during
pregnancy, infancy and childhood. The
developmental thyroid toxicity study
will better address this concern than a
developmental neurotoxicity study. In
an immunotoxicity study, thiabendazole
produced significant decreased spleen
activity at the highest dose tested (5,000
ppm equivalent to 1,027 mg/kg/day)
which also produced significant
increased liver weight. The genetic
toxicology studies on thiabendazole
indicate that it is not genotoxic in in
vivo and in vitro assays. Review of
literature studies indicated that
thiabendazole has weak aneugenic
activity in both somatic and germinal
cells. In a chronic rat study,
thiabendazole induced thyroid tumors
in males only. Thiabendazole did not
induce tumors in mice. Thiabendazole
has been classified by the Agency as
‘‘Likely to be carcinogenic at doses high
enough to cause a disturbance of the
thyroid hormonal balance but not likely
to be carcinogenic at doses lower than
those which could cause a disturbance
of this hormonal balance.’’ This
conclusion is based on the observation
that that thiabendazole was not
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
mutagenic, but above a threshold dose
it interfered with thyroid-pituitary
homeostasis leading to increased
thyroid stimulating hormone (TSH)
stimulation of the thyroid and thyroid
tumors. The chronic NOAEL (10 mg/kg/
day) for non-cancer risk assessment is
not expected to alter thyroid hormone
homeostasis nor result in thyroid tumor
formation; therefore, the Agency has
determined that quantification of risk
using a non-linear approach (i.e.,
chronic population adjusted dose
(cPAD)) will adequately account for all
chronic toxicity, including
carcinogenicity, that could result from
exposure to thiabendazole.
Specific information on the studies
received and the nature of the adverse
effects caused by thiabendazole as well
as the no-observed-adverse-effect-level
(NOAEL) and the lowest-observedadverse-effect-level (LOAEL) from the
toxicity studies can be found at https://
www.regulations.gov in the document
titled ‘‘Thiabendazole: ID#16NC02—
Section 18 Specific Emergency
Exemption for the Postharvest Use of
Thiabendazole on Sweet Potatoes in
North Carolina’’ on page 32 in docket ID
number EPA–HQ–OPP–2015–0554.
B. Toxicological Points of Departure/
Levels of Concern
Once a pesticide’s toxicological
profile is determined, EPA identifies
toxicological points of departure (POD)
and levels of concern to use in
evaluating the risk posed by human
exposure to the pesticide. For hazards
that have a threshold below which there
is no appreciable risk, the toxicological
POD is used as the basis for derivation
of reference values for risk assessment.
PODs are developed based on a careful
analysis of the doses in each
toxicological study to determine the
dose at which no adverse effects are
observed (the NOAEL) and the lowest
dose at which adverse effects of concern
are identified (the LOAEL). Uncertainty/
safety factors are used in conjunction
with the POD to calculate a safe
exposure level—generally referred to as
a population-adjusted dose (PAD) or a
reference dose (RfD)—and a safe margin
of exposure (MOE). For non-threshold
risks, the Agency assumes that any
amount of exposure will lead to some
degree of risk. Thus, the Agency
estimates risk in terms of the probability
of an occurrence of the adverse effect
expected in a lifetime. For more
information on the general principles
EPA uses in risk characterization and a
complete description of the risk
assessment process, see https://
www2.epa.gov/pesticide-science-and-
PO 00000
Frm 00027
Fmt 4700
Sfmt 4700
65291
assessing-pesticide-risks/assessinghuman-health-risk-pesticides.
A summary of the toxicological
endpoints for thiabendazole used for
human risk assessment is discussed in
Unit III.B. of the final rule published in
the Federal Register of September 25,
2014 (79 FR 57450) (FRL–9915–78).
C. Exposure Assessment
1. Dietary exposure from food and
feed uses. In evaluating dietary
exposure to thiabendazole, EPA
considered exposure under the
petitioned-for tolerances and the
tolerance being established in response
to the Agency issuing a section 18
emergency exemption, as well as all
existing thiabendazole tolerances in 40
CFR 180.242. EPA assessed dietary
exposures from thiabendazole in food as
follows:
i. Acute exposure. Quantitative acute
dietary exposure and risk assessments
are performed for a food-use pesticide if
a toxicological study has indicated the
possibility of an effect of concern
occurring as a result of a 1-day or single
exposure.
Such effects were identified for
thiabendazole. In estimating acute
dietary exposure, EPA used 2003–2008
food consumption data from the U.S.
Department of Agriculture’s (USDA’s)
National Health and Nutrition
Examination Survey, What We Eat in
America (NHANES/WWEIA). As to
residue levels in food, EPA used a
refined acute probabilistic dietary
exposure assessment for thiabendazole
using both anticipated residue estimates
based on USDA Pesticide Data Program
(PDP) monitoring data and percent crop
treated (PCT) information for soybean
and wheat and assumed 100 PCT for all
other commodities.
ii. Chronic exposure. In conducting
the chronic dietary exposure assessment
EPA used 2003–2008 food consumption
data from the USDA’s NHANES/
WWEIA. As to residue levels in food,
EPA used a refined chronic probabilistic
dietary exposure assessment for
thiabendazole using both anticipated
residue estimates based on USDA PDP
monitoring data and PCT information
for soybean and wheat and assumed 100
PCT for all other commodities.
iii. Cancer. Based on the data
summarized in Unit III.A., EPA has
concluded that a nonlinear RfD
approach is appropriate for assessing
cancer risk to thiabendazole. Cancer risk
was assessed using the same exposure
estimates as discussed in Unit III.C.1.ii.,
chronic exposure.
iv. Anticipated residue and percent
crop treated (PCT) information. Section
408(b)(2)(E) of FFDCA authorizes EPA
E:\FR\FM\22SER1.SGM
22SER1
65292
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
to use available data and information on
the anticipated residue levels of
pesticide residues in food and the actual
levels of pesticide residues that have
been measured in food. If EPA relies on
such information, EPA must require
pursuant to FFDCA section 408(f)(1)
that data be provided 5 years after the
tolerance is established, modified, or
left in effect, demonstrating that the
levels in food are not above the levels
anticipated. For the present action, EPA
will issue such data call-ins as are
required by FFDCA section 408(b)(2)(E)
and authorized under FFDCA section
408(f)(1). Data will be required to be
submitted no later than 5 years from the
date of issuance of these tolerances.
Section 408(b)(2)(F) of FFDCA states
that the Agency may use data on the
actual percent of food treated for
assessing chronic dietary risk only if:
• Condition a: The data used are
reliable and provide a valid basis to
show what percentage of the food
derived from such crop is likely to
contain the pesticide residue.
• Condition b: The exposure estimate
does not underestimate exposure for any
significant subpopulation group.
• Condition c: Data are available on
pesticide use and food consumption in
a particular area, the exposure estimate
does not understate exposure for the
population in such area.
In addition, the Agency must provide
for periodic evaluation of any estimates
used. To provide for the periodic
evaluation of the estimate of PCT as
required by FFDCA section 408(b)(2)(F),
EPA may require registrants to submit
data on PCT.
For the acute assessment, the Agency
estimated the PCT for existing uses as
follows:
Soybeans, 2.5%; wheat, 2.5%.
For the chronic assessment, the
Agency estimated the PCT for existing
uses as follows:
ehiers on DSK5VPTVN1PROD with RULES
Soybeans, 1%; wheat, 1%.
In most cases, EPA uses available data
from United States Department of
Agriculture/National Agricultural
Statistics Service (USDA/NASS),
proprietary market surveys, and the
National Pesticide Use Database for the
chemical/crop combination for the most
recent 6–7 years. EPA uses an average
PCT for chronic dietary risk analysis.
The average PCT figure for each existing
use is derived by combining available
public and private market survey data
for that use, averaging across all
observations, and rounding to the
nearest 5%, except for those situations
in which the average PCT is less than
one. In those cases, 1% is used as the
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
average PCT and 2.5% is used as the
maximum PCT. EPA uses a maximum
PCT for acute dietary risk analysis. The
maximum PCT figure is the highest
observed maximum value reported
within the recent 6 years of available
public and private market survey data
for the existing use and rounded up to
the nearest multiple of 5%.
The Agency believes that the three
conditions discussed in Unit III.C.1.iv.
have been met. With respect to
Condition a, PCT estimates are derived
from Federal and private market survey
data, which are reliable and have a valid
basis. The Agency is reasonably certain
that the percentage of the food treated
is not likely to be an underestimation.
As to Conditions b and c, regional
consumption information and
consumption information for significant
subpopulations is taken into account
through EPA’s computer-based model
for evaluating the exposure of
significant subpopulations including
several regional groups. Use of this
consumption information in EPA’s risk
assessment process ensures that EPA’s
exposure estimate does not understate
exposure for any significant
subpopulation group and allows the
Agency to be reasonably certain that no
regional population is exposed to
residue levels higher than those
estimated by the Agency. Other than the
data available through national food
consumption surveys, EPA does not
have available reliable information on
the regional consumption of food to
which thiabendazole may be applied in
a particular area.
2. Dietary exposure from drinking
water. The Agency used screening level
water exposure models in the dietary
exposure analysis and risk assessment
for thiabendazole in drinking water.
These simulation models take into
account data on the physical, chemical,
and fate/transport characteristics of
thiabendazole. Further information
regarding EPA drinking water models
used in pesticide exposure assessment
can be found at https://www2.epa.gov/
pesticide-science-and-assessingpesticide-risks/about-water-exposuremodels-used-pesticide.
Based on the FQPA Index Reservoir
Screening Tool (FIRST) and Pesticide
Root Zone Model GroundWater (PRZM–
GW), the estimated drinking water
concentrations (EDWCs) of
thiabendazole for acute exposures are
estimated to be 3.80 parts per billion
(ppb) for surface water and 0.62 ppb for
ground water, and for chronic exposures
are estimated to be 0.47 ppb for surface
water.
Modeled estimates of drinking water
concentrations were directly entered
PO 00000
Frm 00028
Fmt 4700
Sfmt 4700
into the dietary exposure model. For the
acute dietary risk assessment, the water
concentration value of 3.80 ppb was
used to assess the contribution to
drinking water.
For the chronic dietary risk
assessment, the water concentration of
value 0.47 ppb was used to assess the
contribution to drinking water.
3. From non-dietary exposure. The
term ‘‘residential exposure’’ is used in
this document to refer to nonoccupational, non-dietary exposure
(e.g., for lawn and garden pest control,
indoor pest control, termiticides, and
flea and tick control on pets).
Thiabendazole is currently registered
for use as antimicrobial ingredient in
paint, sponges, carpet backing, canvas
textiles, wallboard and ceiling tiles,
polyurethane foam, plastics and rubber,
paper, and coatings and filters used in
HVAC systems. There are two
antimicrobial exposure scenarios that
were assessed for residential exposures
which are expected to result in the
highest exposures from these
antimicrobial uses: Treated paint and
impregnated sponges. The other
antimicrobial uses of thiabendazole
(carpet backing, canvas textiles,
wallboard and ceiling tiles,
polyurethane foam, plastics and rubber,
paper, and coatings and filters used in
HVAC systems) are not expected to
cause exposure in residential settings
because there is no direct contact to the
treated articles, the vapor pressure of
thiabendazole is very low, and the
unlikelihood that the treated plastics
and rubbers would be used in toys.
EPA assessed residential exposure to
treated paint and impregnated sponges
using the following assumptions: For
treated paint, residential short-term
dermal and inhalation exposure to
residential handlers using brush/roller
application and airless sprayer
application; for the impregnated sponge
use, short- and intermediate-term
incidental oral exposure. Thiabendazole
treated sponges are limited to 600 ppm
thiabendazole on a sponge. Various
residue amounts may be transferred
from the sponge to food contact
surfaces, such as countertops and
utensils/glassware, and then to food and
subsequently ingested. An assessment
was conducted for incidental oral
exposure assuming that 100% of the
thiabendazole on a treated sponge is
transferred to surfaces over 20 days and
that each 20 days the user would use a
new sponge (5% released per day). This
assumption is considered conservative
because (1) sponges will generally be
used much longer than 20 days; (2) it is
unlikely that 100% of the thiabendazole
would be released from the sponge in
E:\FR\FM\22SER1.SGM
22SER1
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
ehiers on DSK5VPTVN1PROD with RULES
such a short period; and (3) it is very
unlikely that 100% of any released
thiabendazole would be transferred to
countertops because this assumption
does not account any thiabendazole that
is washed down the sink or that
normally degrades.
Further information regarding EPA
standard assumptions and generic
inputs for residential exposures may be
found at https://www2.epa.gov/pesticidescience-and-assessing-pesticide-risks/
standard-operating-proceduresresidential-pesticide.
4. Cumulative effects from substances
with a common mechanism of toxicity.
Section 408(b)(2)(D)(v) of FFDCA
requires that, when considering whether
to establish, modify, or revoke a
tolerance, the Agency consider
‘‘available information’’ concerning the
cumulative effects of a particular
pesticide’s residues and ‘‘other
substances that have a common
mechanism of toxicity.’’
EPA has not found thiabendazole to
share a common mechanism of toxicity
with any other substances, and
thiabendazole does not appear to
produce a toxic metabolite produced by
other substances. For the purposes of
this tolerance action, therefore, EPA has
assumed that thiabendazole does not
have a common mechanism of toxicity
with other substances. For information
regarding EPA’s efforts to determine
which chemicals have a common
mechanism of toxicity and to evaluate
the cumulative effects of such
chemicals, see EPA’s Web site at https://
www2.epa.gov/pesticide-science-andassessing-pesticide-risks/cumulativeassessment-risk-pesticides.
D. Safety Factor for Infants and
Children
1. In general. Section 408(b)(2)(C) of
FFDCA provides that EPA shall apply
an additional tenfold (10X) margin of
safety for infants and children in the
case of threshold effects to account for
prenatal and postnatal toxicity and the
completeness of the database on toxicity
and exposure unless EPA determines
based on reliable data that a different
margin of safety will be safe for infants
and children. This additional margin of
safety is commonly referred to as the
Food Quality Protection Act Safety
Factor (FQPA SF). In applying this
provision, EPA either retains the default
value of 10X, or uses a different
additional safety factor when reliable
data available to EPA support the choice
of a different factor.
2. Prenatal and postnatal sensitivity.
No evidence of increased quantitative or
qualitative susceptibility was seen
following in utero exposure to
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
thiabendazole with rats or rabbits in the
prenatal developmental studies or in
young rats in the 2-generation
reproduction study. There is no
evidence for neurotoxicity following
oral exposures to thiabendazole.
Thyroid toxicity was seen following
subchronic and chronic exposures to
adult rats in multiple studies. There is,
however, no data regarding the potential
effects of thiabendazole on thyroid
homeostasis in the young animals. This
lack of characterization creates
uncertainty with regards to potential life
stage sensitivities due to exposure to
thiabendazole. Therefore, the Agency is
requiring a developmental thyroid assay
in rats with thiabendazole. This study
will better address the concern for
potential thyroid toxicity in the young.
3. Conclusion. EPA has determined
that reliable data show the safety of
infants and children would be
adequately protected if the FQPA SF is
retained at 10X in the form of a database
uncertainty factor (UFDB). That
decision is based on the following
findings:
i. The toxicology database for
thiabendazole is complete with the
exception of a developmental thyroid
toxicity study. Based on a WOE
approach considering all the available
hazard and exposure information for
thiabendazole, the Agency concluded
that a developmental thyroid toxicity
study is required since there is clear
evidence of thyroid toxicity in adult
animals and thus a concern for potential
toxicity during pregnancy, infancy and
childhood. The developmental thyroid
toxicity study will better address this
concern than a developmental
neurotoxicity study. Acceptable studies
are available for developmental,
reproduction, chronic, subchronic,
subchronic neurotoxicity and
immunotoxicity.
ii. There is no indication that
thiabendazole is a neurotoxic chemical
and there is no need for a
developmental neurotoxicity study or
additional UFs to account for
neurotoxicity.
iii. The data submitted to the Agency,
as well as those from published
literature, demonstrate no increased
susceptibility in rats, rabbits, or mice to
in utero and/or early postnatal exposure
to thiabendazole. In the prenatal
developmental toxicity studies in rats,
rabbits, and mice and in the 2generations reproduction study in rats,
developmental effects in the fetuses or
neonates occurred at or above doses that
caused maternal or parental toxicity. A
developmental neurotoxicity study with
thiabendazole was deemed not required
by the Agency.
PO 00000
Frm 00029
Fmt 4700
Sfmt 4700
65293
There is evidence of thyroid toxicity
following subchronic and chronic
exposures to rats characterized as
histopathological changes in the thyroid
in multiple studies in rats. Disruption of
thyroid homeostasis is the initial,
critical effect that may lead to adverse
effects on the developing nervous
system. Thus, as noted above, a
developmental thyroid study is
required.
iv. There are no residual uncertainties
in the exposure database. The dietary
risk assessment is conservative and will
not underestimate dietary and/or nondietary occupational exposure to
thiabendazole. The acute and chronic
dietary assessments conducted with the
Dietary Exposure Evaluation Model
software with the Food Commodity
Intake Database (DEEM–FCID) were
refined analyses. The assessments
utilized anticipated residues, default
processing factors, and available percent
crop treated data. The DEEM analysis
also used Tier 1 drinking water
estimates. For these reasons it can be
concluded that the DEEM–FCID analysis
does not underestimate risk from acute
or chronic exposure to thiabendazole.
Similarly, EPA does not believe that the
non-dietary occupational exposures are
underestimated because they are also
based on conservative assumptions,
including maximum application rates,
and standard values for unit exposures
and acreage treated/amount handled.
These assessments will not
underestimate the exposure and risks
posed by thiabendazole.
E. Aggregate Risks and Determination of
Safety
EPA determines whether acute and
chronic dietary pesticide exposures are
safe by comparing aggregate exposure
estimates to the acute PAD (aPAD) and
chronic PAD (cPAD). For linear cancer
risks, EPA calculates the lifetime
probability of acquiring cancer given the
estimated aggregate exposure. Short-,
intermediate-, and chronic-term risks
are evaluated by comparing the
estimated aggregate food, water, and
residential exposure to the appropriate
PODs to ensure that an adequate MOE
exists.
1. Acute risk. Using the exposure
assumptions discussed in this unit for
acute exposure, the acute dietary
exposure from food and water to
thiabendazole at the 99.9th percentile of
exposure will occupy 68% of the aPAD
for children 1–2 years old, the
population group receiving the greatest
exposure.
2. Chronic risk. Using the exposure
assumptions described in this unit for
chronic exposure, EPA has concluded
E:\FR\FM\22SER1.SGM
22SER1
65294
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
that chronic exposure to thiabendazole
from food and water will utilize 5.1% of
the cPAD for children 1–2 years old, the
population group receiving the greatest
exposure. Based on the explanation in
Unit III.C.3., regarding residential use
patterns, chronic residential exposure to
residues of thiabendazole is not
expected.
3. Short- and intermediate-term risk.
Short- and intermediate-term aggregate
exposure takes into account short- and
intermediate-term residential exposure
plus chronic exposure to food and water
(considered to be a background
exposure level).
Thiabendazole is currently registered
for uses that could result in short- and
intermediate-term residential exposure,
and the Agency has determined that it
is appropriate to aggregate chronic
exposure through food and water with
short- and intermediate-term residential
exposures to thiabendazole.
Using the exposure assumptions
described in this unit for short- and
intermediate-term exposures, EPA has
concluded the combined short- and
intermediate-term food, water, and
residential exposures result in aggregate
MOEs from the paint use of 2,000 or
greater for all population subgroups and
aggregate MOEs from the sponge use of
1,400 for children 1–2 years old and
7,000 for the general population.
Because EPA’s level of concern for
thiabendazole is a MOE of 300 or below,
these MOEs are not of concern.
4. Aggregate cancer risk for U.S.
population. As discussed in Unit III.A.,
EPA is regulating chronic dietary risk,
including cancer risk, with a chronic
RfD that reflects a dose level below
those levels at which thyroid hormone
balance is impacted, which is protective
of potential carcinogenic effects. Based
on the lack of chronic risk, EPA
concludes there is not a cancer risk from
exposure to thiabendazole.
5. Determination of safety. Based on
these risk assessments, EPA concludes
that there is a reasonable certainty that
no harm will result to the general
population, or to infants and children
from aggregate exposure to
thiabendazole residues.
IV. Other Considerations
ehiers on DSK5VPTVN1PROD with RULES
A. Analytical Enforcement Methodology
Acceptable enforcement analytical
methods are available for thiabendazole
and benzimidazole in plant
commodities. Four
spectrophotofluorometric methods for
the determination of thiabendazole are
published in the Pesticide Analytical
Manual (PAM) Vol. II, and a high
performance liquid chromatography
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
(HPLC) method with fluorescence
detection (FLD) for the determination of
benzimidazole (free and conjugated) is
identified in the U.S. EPA Index of
Residue Analytical Methods under
thiabendazole as Study No. 93020.
Another adequate analytical method,
GRM040.05A, is also available for data
collection and tolerance enforcement of
residues of thiabendazole and
benzimidazole (free and conjugated) in/
on plant commodities. Method
GRM040.05A, developed by Syngenta
Crop Protection, LLC, is a high
performance liquid chromatography
with tandem mass spectrometry
detection (LC/MS/MS) method used for
data collection in crop matrices. HED
has designated Method GRM040.05A as
a new tolerance enforcement method.
Both methods may be requested from:
Chief, Analytical Chemistry Branch,
Environmental Science Center, 701
Mapes Rd., Ft. Meade, MD 20755–5350;
telephone number: (410) 305–2905;
email address: residuemethods@
epa.gov.
B. International Residue Limits
In making its tolerance decisions, EPA
seeks to harmonize U.S. tolerances with
international standards whenever
possible, consistent with U.S. food
safety standards and agricultural
practices. EPA considers the
international maximum residue limits
(MRLs) established by the Codex
Alimentarius Commission (Codex), as
required by FFDCA section 408(b)(4).
The Codex Alimentarius is a joint
United Nations Food and Agriculture
Organization/World Health
Organization food standards program,
and it is recognized as an international
food safety standards-setting
organization in trade agreements to
which the United States is a party. EPA
may establish a tolerance that is
different from a Codex MRL; however,
FFDCA section 408(b)(4) requires that
EPA explain the reasons for departing
from the Codex level.
The Codex has not established a MRL
for thiabendazole on any of the
commodities cited in this document.
C. Response to Comments
A comment was submitted by the
Center for Food Safety and was
primarily concerned about EPA’s
consideration of the impacts of
thiabendazole on the environment,
pollinators, and endangered species.
This comment is not relevant to the
Agency’s evaluation of safety of the
thiabendazole tolerances under section
408 of the FFDCA, which requires the
Agency to evaluate the potential harms
PO 00000
Frm 00030
Fmt 4700
Sfmt 4700
to human health, not effects on the
environment.
D. Revisions to Petitioned-For
Tolerances
The petitioned-for tolerances did not
include measurement of benzimidazole
(free and conjugated) which is a residue
of concern for regulatory purposes.
Therefore, the petitioned-for tolerance
for the vegetable, legume, group 6 at
0.01 ppm for thiabendazole only, is
adjusted to 0.02 ppm to account for the
combined residues of thiabendazole and
benzimidazole (free and conjugated).
Also, EPA concluded that the maximum
levels of the combined residues of
concern in/on the representative crop
commodities of vegetable, foliage of
legume, group 7 are within 5x, and that
a crop group 7 tolerance level of 0.20
ppm is more appropriate than the
petitioned-for separate tolerances for
pea, field, hay; pea, field, vines; and
vegetable, foliage of legume, group 7,
except pea, field, hay and vines.
E. International Trade Considerations
In this rulemaking, EPA is adding an
expiration date of March 21, 2017 to the
existing tolerances for bean, dry, seed at
0.1 ppm and soybean at 0.1 ppm. These
tolerances were based on foliar uses of
thiabendazole which are no longer
registered and Syngenta requested that
these tolerances be removed as part of
the petition and notice of filing (NOF).
The seed treatment uses on dry bean
seed and soybean is now covered by the
tolerance being established on
vegetable, legume, group 6 at 0.02 ppm.
This new tolerance is lower than some
existing MRLs on these commodities in
Europe and other countries.
In accordance with the World Trade
Organization’s (WTO) Sanitary and
Phytosanitary Measures Agreement,
EPA notified the WTO of the request to
revise these tolerances on September 9,
2015, as WTO notification G/SPS/N/
USA/2779. In this action, EPA is
allowing the existing higher tolerances
to remain in effect for 6 months
following the publication of this rule in
order to allow a reasonable interval for
producers in exporting countries to
adapt to the requirements of these
modified tolerances. On March 21,
2017, those existing higher tolerances
will expire, and the new reduced
tolerances for vegetable, legume, group
6 at 0.02 ppm will remain to cover
residues of thiabendazole on those
commodities. Before that date, residues
of thiabendazole on those commodities
would be permitted up to the higher
tolerance levels; after that date, residues
of thiabendazole on vegetable, legume,
group 6 will need to comply with the
E:\FR\FM\22SER1.SGM
22SER1
65295
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
new lower tolerance levels. This
reduction in tolerance is not
discriminatory; the same food safety
standard contained in the FFDCA
applies equally to domestically
produced and imported foods.
V. Conclusion
Therefore, tolerances are established
for residues of thiabendazole in or on
vegetable, foliage of legume, group 7 at
0.20 ppm and vegetable, legume, group
6 at 0.02 ppm. The Agency is also
adding an expiration date of March 21,
2017 to the existing tolerances for bean,
dry, seed at 0.1 ppm and soybean at 0.1
ppm. Residues of thiabendazole will be
covered by these higher tolerances until
the expiration date, after which time,
they will need to comply with the lower
tolerance being established today on the
vegetable, legume, group 6 at 0.02 ppm.
The tolerance for group 6 without a time
limitation supersedes the existing
section 18 time-limited tolerance for
‘‘pea, succulent shelled’’; therefore, the
Agency is removing that section 18
tolerance.
The Agency is also removing the
threshold of regulation determination
for thiabendazole from 180.2010
because it is no longer necessary. Lastly,
this regulation additionally establishes a
time-limited tolerances for residues of
thiabendazole in or on sweet potato at
10 ppm.
ehiers on DSK5VPTVN1PROD with RULES
VI. Statutory and Executive Order
Reviews
This action establishes tolerances
under FFDCA section 408(d) in
response to a petition submitted to the
Agency. The Office of Management and
Budget (OMB) has exempted these types
of actions from review under Executive
Order 12866, entitled ‘‘Regulatory
Planning and Review’’ (58 FR 51735,
October 4, 1993). Because this action
has been exempted from review under
Executive Order 12866, this action is
not subject to Executive Order 13211,
entitled ‘‘Actions Concerning
Regulations That Significantly Affect
Energy Supply, Distribution, or Use’’ (66
FR 28355, May 22, 2001) or Executive
Order 13045, entitled ‘‘Protection of
Children from Environmental Health
Risks and Safety Risks’’ (62 FR 19885,
April 23, 1997). This action does not
contain any information collections
subject to OMB approval under the
Paperwork Reduction Act (PRA) (44
U.S.C. 3501 et seq.), nor does it require
any special considerations under
Executive Order 12898, entitled
‘‘Federal Actions to Address
Environmental Justice in Minority
Populations and Low-Income
Populations’’ (59 FR 7629, February 16,
1994).
Since tolerances and exemptions that
are established on the basis of a petition
under FFDCA section 408(d), such as
the tolerance in this final rule, do not
require the issuance of a proposed rule,
the requirements of the Regulatory
Flexibility Act (RFA) (5 U.S.C. 601 et
seq.), do not apply.
This action directly regulates growers,
food processors, food handlers, and food
retailers, not States or tribes, nor does
this action alter the relationships or
distribution of power and
responsibilities established by Congress
in the preemption provisions of FFDCA
section 408(n)(4). As such, the Agency
has determined that this action will not
have a substantial direct effect on States
or tribal governments, on the
relationship between the national
government and the States or tribal
governments, or on the distribution of
power and responsibilities among the
various levels of government or between
the Federal Government and Indian
tribes. Thus, the Agency has determined
that Executive Order 13132, entitled
‘‘Federalism’’ (64 FR 43255, August 10,
1999) and Executive Order 13175,
entitled ‘‘Consultation and Coordination
with Indian Tribal Governments’’ (65 FR
67249, November 9, 2000) do not apply
to this action. In addition, this action
does not impose any enforceable duty or
contain any unfunded mandate as
described under Title II of the Unfunded
Mandates Reform Act (UMRA) (2 U.S.C.
1501 et seq.).
This action does not involve any
technical standards that would require
Agency consideration of voluntary
consensus standards pursuant to section
12(d) of the National Technology
Transfer and Advancement Act
(NTTAA) (15 U.S.C. 272 note).
VII. Congressional Review Act
Pursuant to the Congressional Review
Act (5 U.S.C. 801 et seq.), EPA will
submit a report containing this rule and
other required information to the U.S.
Senate, the U.S. House of
Representatives, and the Comptroller
General of the United States prior to
Commodity
10
List of Subjects in 40 CFR Part 180
Environmental protection,
Administrative practice and procedure,
Agricultural commodities, Pesticides
and pests, Reporting and recordkeeping
requirements.
Dated: August 26, 2016.
Michael Goodis,
Acting Director, Registration Division, Office
of Pesticide Programs.
Therefore, 40 CFR chapter I is
amended as follows:
PART 180—[AMENDED]
1. The authority citation for part 180
continues to read as follows:
■
Authority: 21 U.S.C. 321(q), 346a and 371.
2. In § 180.242;
a. Revise the entries ‘‘bean, dry, seed’’
and ‘‘soybean’’ to the table in paragraph
(a)(1);
■ b. Add alphabetically the entries
‘‘Vegetable, foliage of legume, group 7’’
and ‘‘Vegetable, legume, group 6’’ to the
table in paragraph (a)(1)
■ c. Remove the entry for ‘‘Pea,
succulent shelled’’ from the table in
paragraph (b);
■ d. Add alphabetically the entry
‘‘sweet potato’’ to the table in paragraph
(b).
The additions and revisions read as
follows:
■
■
§ 180.242 Thiabendazole; tolerances for
residues.
(a) * * *
(1) * * *
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
PO 00000
Frm 00031
Fmt 4700
*
*
*
Bean, dry, seed 2 ..................
*
*
*
*
Soybean 2 ..............................
*
*
*
*
Vegetable, foliage of legume,
group 7 ..............................
Vegetable, legume, group 6
*
*
*
2 This
December 31, 2019.
E:\FR\FM\22SER1.SGM
*
*
0.1
*
0.1
*
0.20
0.02
*
*
tolerance expires on March 21, 2017.
(b) * * *
Expiration date
Sfmt 4700
Parts per
million
Commodity
Parts per
million
Sweet potato ...............................................................................
publication of the rule in the Federal
Register. This action is not a ‘‘major
rule’’ as defined by 5 U.S.C. 804(2).
22SER1
65296
Federal Register / Vol. 81, No. 184 / Thursday, September 22, 2016 / Rules and Regulations
*
*
*
§ 180.2010
*
*
[Removed and Reserved]
3. Section 180.2010 is removed and
reserved.
■
[FR Doc. 2016–21753 Filed 9–21–16; 8:45 am]
BILLING CODE 6560–50–P
GENERAL SERVICES
ADMINISTRATION
41 CFR Parts 102–117 and 102–118
[Change 2016–01; FMR Case 2015–102–2;
Docket 2015–0014; Sequence 1]
RIN 3090–AJ59
Federal Management Regulation
(FMR); Transportation Payment and
Audit
Office of Government-wide
Policy (OGP), General Services
Administration (GSA).
ACTION: Final rule.
AGENCY:
GSA is amending the Federal
Management Regulation (FMR),
Transportation Payment and Audit, to
clarify agency and Department of
Defense (DoD) transportation payment
and audit requirements. GSA is also
amending relevant definitions. The FMR
is written in plain language to provide
agencies with updated regulatory
material that is easy to read and
understand.
SUMMARY:
Effective: September 22, 2016.
For
clarification of content, contact Mr. Ron
Siegel, Office of Government-wide
Policy, at 202–357–9540 or by email at
ron.siegel@gsa.gov. For information
pertaining to status or publication
schedules, contact the Regulatory
Secretariat Division (MVCB), 1800 F
Street NW., Washington, DC 20405,
202–501–4755. Please cite FMR Case
2015–102–2.
SUPPLEMENTARY INFORMATION:
DATES:
FOR FURTHER INFORMATION CONTACT:
ehiers on DSK5VPTVN1PROD with RULES
A. Background
Agencies are authorized to procure
transportation services either through
the Federal Acquisition Regulation
(FAR) by utilizing a contract, or via 49
U.S.C. 10721 (for rail transportation), 49
U.S.C. 13712 (for surface
transportation), and/or 49 U.S.C. 15504
(for pipeline transportation) by utilizing
rate tenders. It is critical that agencies
ensure that transportation services
received are properly charged and that
the payment made is correct.
Toward that end, the Travel and
Transportation Reform Act of 1998 (Pub.
L. 105–264) established agency statutory
VerDate Sep<11>2014
15:00 Sep 21, 2016
Jkt 238001
requirements for prepayment audits of
Federal agency and DoD transportation
expenses. The Act also established
GSA’s statutory authority for audit
oversight to protect the interests of the
Government.
This final rule clarifies and
strengthens agency and DoD compliance
with regulations for transportation
prepayment audits and postpayment
audits. In addition, this final rule
updates definitions in 41 CFR part 102–
117, Transportation Management, as a
result of the amendments to 41 CFR
102–118.
This final rule is the outcome of the
first of a two phase review of FMR part
102–118, Transportation Payment and
Audit, conducted by GSA and the
Governmentwide Transportation Policy
Council (GTPC). The GTPC is composed
of representatives from civilian agencies
and DoD and provides GSA with
guidance in the planning and
development of uniform transportation
policies and procedures.
The first phase review focused on
FMR part 102–118 Subparts A (General),
D (Prepayment Audits of Transportation
Services), and E (Postpayment
Transportation Audits). The second
phase review will focus on FMR part
102–118 Subpart A (General), as well as
Subparts B (Ordering and Paying for
Transportation and Transportation
Services), C (Use of Government Billing
Documents), and F (Claims and Appeals
Procedures).
B. Public Comments and Responses
In the proposed rule published at 80
FR 59094 in the Federal Register, on
October 1, 2015, GSA provided the
public a 60-day comment period which
ended on November 30, 2015. GSA
received comments from the National
Motor Freight Traffic Association, Inc.
(NMFTA), and Relocation Management
Worldwide Incorporated (RMW). This
final rule reflects the following changes
made as a result of some of these
comments.
Comment: The definition in the
proposed rule for declared value in
FMR 102–117.25 and 102–118.35
contains reference to declared value and
released value. However, NMFTA
indicates that the ‘‘terms ‘declared
value’ and ‘released value’ are neither
synonymous nor recognized by the
transportation industry. A carrier
establishes released value provisions
with the intent of the shipper agreeing
to a lesser value for the cargo shipped
in return for a lower rate for
transportation. Declared value assigns a
value to the cargo in order to
authenticate loss and damage liability
limitations on the cargo that was
PO 00000
Frm 00032
Fmt 4700
Sfmt 4700
shipped. Furthermore, it is inequitable
to define declared value as a price that
could be ‘more’ than the actual value of
the cargo. In commercial practice, a
transportation service provider (TSP)
will not pay a loss or damage claim in
excess of the actual value of the cargo
transported.’’
Response: GSA agrees with the
recommendation and consequently has
modified the definition declared value
that is added to 41 CFR 102–117.25 so
that it does not reference released value;
included a definition for released value
in 41 CFR 102–117.25; and has removed
the definition released value from 41
CFR 102–118.
Comment: With regards to the
definition claim, NMFTA indicates that
in the transportation industry, the term
claim is generally used in the context of
claims for the payment of overcharges or
claims for loss or damage. NMFTA
recommends that any other terms for
demands for payment by the TSP to the
Government or amounts the TSP
believes an agency owes them should
not be included in this definition and
would be better defined separately.
Response: GSA does not accept this
recommendation. The definition of
claim presented in this final rule is
modeled after the definition of claim or
debt found in 31 U.S.C. 3701(b)(1).
Comment: The Government
Transportation Request (GTR) is
defined, in part, as a Government
document used to procure common
carrier interstate transportation services.
NMFTA indicates that as far as
interstate motor carrier transportation is
concerned, the term common carrier is
no longer defined in 49 U.S.C. 13102.
Former common carriers are now
referred to as motor carriers. NFMTA
suggests using the description motor
carrier or TSP which is used elsewhere
in these regulations. NFMTA also
suggests that since the Government can
procure intrastate transportation with a
GTR, it does not make sense to include
the word ‘‘interstate’’ in the final GTR
definition.
Response: The term common carrier
is used to define Government
Transportation Request (GTR) in the
Federal Travel Regulation (FTR). In
response to the comment, GSA has
revised the definition of GTR to clarify
that the document is used to acquire
passenger transportation.
Comment: Standard Carrier Alpha
Code (SCAC) is defined, in part, as the
unique four-letter code used to identify
American-based motor transportation
companies assigned by NMFTA.
NMFTA indicates that the SCAC
definition should be a two-to-four letter
identification code assigned to all
E:\FR\FM\22SER1.SGM
22SER1
Agencies
[Federal Register Volume 81, Number 184 (Thursday, September 22, 2016)]
[Rules and Regulations]
[Pages 65289-65296]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21753]
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
40 CFR Part 180
[EPA-HQ-OPP-2015-0554; FRL-9950-05]
Thiabendazole; Pesticide Tolerances
AGENCY: Environmental Protection Agency (EPA).
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: This regulation establishes tolerances for residues of
thiabendazole in or on the legume vegetable group 6 and foliage of
legume vegetable group 7. Syngenta Crop Protection requested these
tolerances under the Federal Food, Drug, and Cosmetic Act (FFDCA). This
regulation also assigns an expiration date to existing tolerances for
bean, dry, seed at 0.1 part per million (ppm) and soybean at 0.1 ppm as
well as removes a threshold of regulation determination for seed
treatment use of thiabendazole on dry pea (including field pea, pigeon
pea, chickpea or lentil). Lastly, this regulation establishes a time-
limited tolerance on sweet potato. The time-limited tolerance is in
response to EPA's granting of an emergency exemption under the Federal
Insecticide, Fungicide, and Rodenticide Act (FIFRA). The time-limited
tolerance will expire and be revoked on December 31, 2019.
DATES: This regulation is effective September 22, 2016. Objections and
requests for hearings must be received on or before November 21, 2016,
and must be filed in accordance with the instructions provided in 40
CFR part 178 (see also Unit I.C. of the SUPPLEMENTARY INFORMATION).
ADDRESSES: The docket for this action, identified by docket
identification (ID) number EPA-HQ-OPP-2015-0554, is available at https://www.regulations.gov or at the Office of Pesticide Programs Regulatory
Public Docket (OPP Docket) in the Environmental Protection Agency
Docket Center (EPA/DC), West William Jefferson Clinton Bldg., Rm. 3334,
1301 Constitution Ave. NW., Washington, DC 20460-0001. The Public
Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through
Friday, excluding legal holidays. The telephone number for the Public
Reading Room is (202) 566-1744, and the telephone number for the OPP
Docket is (703) 305-5805. Please review the visitor instructions and
additional information about the docket available at https://www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT: Michael Goodis, Registration Division
(7505P), Office of Pesticide Programs, Environmental Protection Agency,
1200 Pennsylvania Ave. NW., Washington, DC 20460-0001; main telephone
number: (703) 305-7090; email address: RDFRNotices@epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this action apply to me?
You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
The following list of North American Industrial Classification System
(NAICS) codes is not intended to be exhaustive, but rather provides a
guide to help readers determine whether this document applies to them.
Potentially affected entities may include:
Crop production (NAICS code 111).
Animal production (NAICS code 112).
Food manufacturing (NAICS code 311).
Pesticide manufacturing (NAICS code 32532).
B. How can I get electronic access to other related information?
You may access a frequently updated electronic version of EPA's
tolerance regulations at 40 CFR part 180 through the Government
Printing Office's e-CFR site at https://www.ecfr.gov/cgi-bin/text-idx?&c=ecfr&tpl=/ecfrbrowse/Title40/40tab_02.tpl.
C. How can I file an objection or hearing request?
Under FFDCA section 408(g), 21 U.S.C. 346a, any person may file an
objection to any aspect of this regulation and may also request a
hearing on those objections. You must file your objection or request a
hearing on this regulation in accordance with the instructions provided
in 40 CFR part 178. To ensure proper receipt by EPA, you must identify
docket ID number EPA-HQ-OPP-2015-0554 in the subject line on the first
page of your submission. All objections and requests for a hearing must
be in writing, and must be received by the Hearing Clerk on or before
November 21, 2016. Addresses for mail and hand delivery of objections
and hearing requests are provided in 40 CFR 178.25(b).
In addition to filing an objection or hearing request with the
Hearing Clerk as described in 40 CFR part 178, please submit a copy of
the filing (excluding any Confidential Business Information (CBI)) for
inclusion in the public docket. Information not marked confidential
pursuant to 40 CFR part 2 may be disclosed publicly by EPA without
prior notice. Submit the non-CBI copy of your objection or hearing
request, identified by docket ID number EPA-HQ-OPP-2015-0554, by one of
the following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the online instructions for submitting comments. Do not submit
electronically any information you consider to be CBI or other
information whose disclosure is restricted by statute.
Mail: OPP Docket, Environmental Protection Agency Docket
Center (EPA/DC), (28221T), 1200 Pennsylvania Ave. NW., Washington, DC
20460-0001.
Hand Delivery: To make special arrangements for hand
delivery or delivery of boxed information, please follow the
instructions at https://www.epa.gov/dockets/contacts.html.
Additional instructions on commenting or visiting the docket, along
with more information about dockets generally, is available at https://www.epa.gov/dockets.
II. Summary of Agency's Action
A. Petitioned-For Tolerances
In the Federal Register of September 9, 2015 (80 FR 54257) (FRL-
9933-26), EPA issued a document pursuant to FFDCA section 408(d)(3), 21
U.S.C. 346a(d)(3), announcing the filing of a pesticide petition (PP
5F8368) by Syngenta Crop Protection, LLC, P.O. Box 18300, Greensboro,
NC 27419. The petition requested that 40 CFR 180.242
[[Page 65290]]
be amended by establishing tolerances for residues of the fungicide
thiabendazole in or on legume vegetables (succulent or dried), crop
group 6 at 0.01 parts per million (ppm); foliage of legume vegetables,
crop group 7, except pea, field, hay and vines at 0.01 ppm; pea, field,
hay at 0.15 ppm; and pea, field, vines at 0.03 ppm. The petition also
requested to amend the tolerances in 40 CFR 180.242 for residues of
thiabendazole by removing the tolerances in or on bean, dry, seed at
0.1 ppm and soybean at 0.1 ppm. That document referenced a summary of
the petition prepared by Syngenta, the registrant, which is available
in the docket, https://www.regulations.gov. A comment was received on
the notice of filing. EPA's response to this comment is discussed in
Unit IV.C.
Based upon review of the data supporting the petition, EPA has
modified levels at which the tolerances are being established by this
document. The reason for these changes are explained in Unit IV.D.
B. Thiabendazole Threshold of Regulation Determination
In 2008, EPA established a rule codifying its determination that
the use of thiabendazole as a seed treatment for dry pea using a
maximum application rate of 0.075 pound of active ingredient per 100
pounds of seed did not require a tolerance because residues were below
the Agency's threshold of regulation. (73 FR 1976 (Jan. 11, 2008); see
40 CFR 180.2010). The new tolerances for residues of thiabendazole on
crop group 6 legume vegetable commodities, including dry pea, and on
crop group 7, foliage of legume vegetable commodities, which includes
vines and hay from the legume vegetables that the Agency is
establishing make the existing threshold of regulation determination
unnecessary. The new tolerances cover residues on these commodities
resulting from new seed treatment uses that allow for higher
application rates and thus residues associated uses covered by the
threshold of regulation determination are covered by the new
tolerances. As a result, the Agency is removing this determination from
section 180.2010.
C. Tolerance for Use of Pesticide Under Emergency Exemption
In response to a crisis exemption request and authorization of a
specific exemption request filed under section 18 of the Federal
Insecticide, Fungicide, and Rodenticide Act (FIFRA) on behalf of the
North Carolina Department of Agriculture and Consumer Services for the
emergency use of thiabendazole to control black rot disease on sweet
potato, EPA is establishing pursuant to FFDCA section 408(l)(6) time-
limited tolerances for the use of thiabendazole on sweet potato at 10
ppm with an expiration date of December 31, 2019.
As part of its evaluation of the emergency exemption application,
EPA assessed the potential risks presented by residues of thiabendazole
on sweet potato. In doing so, EPA considered the safety standard in
section 408(b)(2) of FFDCA, and the Agency decided that the necessary
tolerance under section 408(l)(6) of FFDCA would be consistent with the
safety standard and with FIFRA section 18. Consistent with the need to
move quickly on the emergency exemption in order to address an urgent
non-routine situation and to ensure that the resulting food is safe and
lawful, EPA is issuing this tolerance without notice and opportunity
for public comment as provided in section 408(l)(6) of FFDCA. Although
this time-limited tolerance expires and is revoked on December 31,
2019, under section 408(l)(5) of FFDCA, residues of the pesticide not
in excess of the amounts specified in the tolerance remaining in or on
sweet potato after that date will not be unlawful, provided the
pesticide was applied in a manner that was lawful under FIFRA, and the
residues do not exceed a level that was authorized by the time-limited
tolerance at the time of that application. EPA will take action to
revoke this time-limited tolerance earlier if any experience with,
scientific data on, or other relevant information on this pesticide
indicate that the residues are not safe.
Because this time-limited tolerance is being approved under
emergency conditions, EPA has not made any decisions whether
thiabendazole meets FIFRA's registration requirements for use in or on
sweet potato or whether a permanent tolerance for this use would be
appropriate. Under these circumstances, EPA does not believe that this
time-limited tolerances serves as a basis for registration of
thiabendazole by a State for Special Local Needs under FIFRA section
24(c). Nor does this tolerance serve as the basis for persons in any
State other than North Carolina to use this pesticide on sweet potato
under FIFRA section 18 absent the issuance of an emergency exemption
applicable within that State. For additional information regarding the
emergency exemption for thiabendazole, contact the Agency's
Registration Division at the address provided under FOR FURTHER
INFORMATION CONTACT.
III. Aggregate Risk Assessment and Determination of Safety
Section 408(b)(2)(A)(i) of FFDCA allows EPA to establish a
tolerance (the legal limit for a pesticide chemical residue in or on a
food) only if EPA determines that the tolerance is ``safe.'' Section
408(b)(2)(A)(ii) of FFDCA defines ``safe'' to mean that ``there is a
reasonable certainty that no harm will result from aggregate exposure
to the pesticide chemical residue, including all anticipated dietary
exposures and all other exposures for which there is reliable
information.'' This assessment includes exposure through drinking water
and in residential settings, but does not include occupational
exposure. Section 408(b)(2)(C) of FFDCA requires EPA to give special
consideration to exposure of infants and children to the pesticide
chemical residue in establishing a tolerance and to ``ensure that there
is a reasonable certainty that no harm will result to infants and
children from aggregate exposure to the pesticide chemical residue . .
. .''
Consistent with FFDCA section 408(b)(2)(D), and the factors
specified in FFDCA section 408(b)(2)(D), EPA has reviewed the available
scientific data and other relevant information in support of this
action. EPA has sufficient data to assess the hazards of and to make a
determination on aggregate exposure for thiabendazole including
exposure resulting from the tolerances, including the time-limited
tolerance, established by this action. EPA's assessment of exposures
and risks associated with thiabendazole follows.
A. Toxicological Profile
EPA has evaluated the available toxicity data and considered its
validity, completeness, and reliability as well as the relationship of
the results of the studies to human risk. EPA has also considered
available information concerning the variability of the sensitivities
of major identifiable subgroups of consumers, including infants and
children.
The thyroid and liver (centrilobular hypertrophy) are the primary
target organs of thiabendazole toxicity. Thiabendazole produced a
treatment related increase in absolute and relative liver weights in
both sexes in a chronic dog study. Other treatment related effects
reported were histopathological changes in kidneys (hyperplasia of
transitional epithelium, tubular degeneration) and spleen (congested
and pigmented) in rats. Additional toxic effects observed in these
studies included decreases in body weight and/or food consumption. The
available
[[Page 65291]]
database indicates that thiabendazole is not neurotoxic. In an acute
neurotoxicity rat study (ACN), decreases in the Functional Observation
Battery (FOB) (reduced body temperature in males, reduced rearing in
females, and reduced locomotor activity in males and females at time of
peak effect (approximately 3 hours post-dose)) were seen without
morphological or histopathological effects on the brain. Thiabendazole
was not neurotoxic in rats in a subchronic neurotoxicity study. In a
21-day dermal toxicity study in rats, no systemic or dermal effects
were seen at the limit dose (1,000 milligram/kilogram/day (mg/kg/day)).
In prenatal developmental toxicity studies in rats, rabbits, and mice
and in the 2-generation reproduction study in rats, effects in the
fetuses or neonates occurred at or above doses that caused maternal or
parental toxicity.
In the adult animal, effects on the thyroid following thiabendazole
exposure were observed at a dose lower than the neurotoxicity dose
observed in the ACN. There are no thiabendazole data with which to
determine whether this is also the case in the fetus/postnatal animal.
Based on a weight of evidence (WOE) approach considering all the
available hazard and exposure information for thiabendazole, the Agency
concluded that a developmental thyroid toxicity study is required since
there is clear evidence of thyroid toxicity in adult animals and thus a
concern for potential toxicity during pregnancy, infancy and childhood.
The developmental thyroid toxicity study will better address this
concern than a developmental neurotoxicity study. In an immunotoxicity
study, thiabendazole produced significant decreased spleen activity at
the highest dose tested (5,000 ppm equivalent to 1,027 mg/kg/day) which
also produced significant increased liver weight. The genetic
toxicology studies on thiabendazole indicate that it is not genotoxic
in in vivo and in vitro assays. Review of literature studies indicated
that thiabendazole has weak aneugenic activity in both somatic and
germinal cells. In a chronic rat study, thiabendazole induced thyroid
tumors in males only. Thiabendazole did not induce tumors in mice.
Thiabendazole has been classified by the Agency as ``Likely to be
carcinogenic at doses high enough to cause a disturbance of the thyroid
hormonal balance but not likely to be carcinogenic at doses lower than
those which could cause a disturbance of this hormonal balance.'' This
conclusion is based on the observation that that thiabendazole was not
mutagenic, but above a threshold dose it interfered with thyroid-
pituitary homeostasis leading to increased thyroid stimulating hormone
(TSH) stimulation of the thyroid and thyroid tumors. The chronic NOAEL
(10 mg/kg/day) for non-cancer risk assessment is not expected to alter
thyroid hormone homeostasis nor result in thyroid tumor formation;
therefore, the Agency has determined that quantification of risk using
a non-linear approach (i.e., chronic population adjusted dose (cPAD))
will adequately account for all chronic toxicity, including
carcinogenicity, that could result from exposure to thiabendazole.
Specific information on the studies received and the nature of the
adverse effects caused by thiabendazole as well as the no-observed-
adverse-effect-level (NOAEL) and the lowest-observed-adverse-effect-
level (LOAEL) from the toxicity studies can be found at https://www.regulations.gov in the document titled ``Thiabendazole: ID#16NC02--
Section 18 Specific Emergency Exemption for the Postharvest Use of
Thiabendazole on Sweet Potatoes in North Carolina'' on page 32 in
docket ID number EPA-HQ-OPP-2015-0554.
B. Toxicological Points of Departure/Levels of Concern
Once a pesticide's toxicological profile is determined, EPA
identifies toxicological points of departure (POD) and levels of
concern to use in evaluating the risk posed by human exposure to the
pesticide. For hazards that have a threshold below which there is no
appreciable risk, the toxicological POD is used as the basis for
derivation of reference values for risk assessment. PODs are developed
based on a careful analysis of the doses in each toxicological study to
determine the dose at which no adverse effects are observed (the NOAEL)
and the lowest dose at which adverse effects of concern are identified
(the LOAEL). Uncertainty/safety factors are used in conjunction with
the POD to calculate a safe exposure level--generally referred to as a
population-adjusted dose (PAD) or a reference dose (RfD)--and a safe
margin of exposure (MOE). For non-threshold risks, the Agency assumes
that any amount of exposure will lead to some degree of risk. Thus, the
Agency estimates risk in terms of the probability of an occurrence of
the adverse effect expected in a lifetime. For more information on the
general principles EPA uses in risk characterization and a complete
description of the risk assessment process, see https://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/assessing-human-health-risk-pesticides.
A summary of the toxicological endpoints for thiabendazole used for
human risk assessment is discussed in Unit III.B. of the final rule
published in the Federal Register of September 25, 2014 (79 FR 57450)
(FRL-9915-78).
C. Exposure Assessment
1. Dietary exposure from food and feed uses. In evaluating dietary
exposure to thiabendazole, EPA considered exposure under the
petitioned-for tolerances and the tolerance being established in
response to the Agency issuing a section 18 emergency exemption, as
well as all existing thiabendazole tolerances in 40 CFR 180.242. EPA
assessed dietary exposures from thiabendazole in food as follows:
i. Acute exposure. Quantitative acute dietary exposure and risk
assessments are performed for a food-use pesticide if a toxicological
study has indicated the possibility of an effect of concern occurring
as a result of a 1-day or single exposure.
Such effects were identified for thiabendazole. In estimating acute
dietary exposure, EPA used 2003-2008 food consumption data from the
U.S. Department of Agriculture's (USDA's) National Health and Nutrition
Examination Survey, What We Eat in America (NHANES/WWEIA). As to
residue levels in food, EPA used a refined acute probabilistic dietary
exposure assessment for thiabendazole using both anticipated residue
estimates based on USDA Pesticide Data Program (PDP) monitoring data
and percent crop treated (PCT) information for soybean and wheat and
assumed 100 PCT for all other commodities.
ii. Chronic exposure. In conducting the chronic dietary exposure
assessment EPA used 2003-2008 food consumption data from the USDA's
NHANES/WWEIA. As to residue levels in food, EPA used a refined chronic
probabilistic dietary exposure assessment for thiabendazole using both
anticipated residue estimates based on USDA PDP monitoring data and PCT
information for soybean and wheat and assumed 100 PCT for all other
commodities.
iii. Cancer. Based on the data summarized in Unit III.A., EPA has
concluded that a nonlinear RfD approach is appropriate for assessing
cancer risk to thiabendazole. Cancer risk was assessed using the same
exposure estimates as discussed in Unit III.C.1.ii., chronic exposure.
iv. Anticipated residue and percent crop treated (PCT) information.
Section 408(b)(2)(E) of FFDCA authorizes EPA
[[Page 65292]]
to use available data and information on the anticipated residue levels
of pesticide residues in food and the actual levels of pesticide
residues that have been measured in food. If EPA relies on such
information, EPA must require pursuant to FFDCA section 408(f)(1) that
data be provided 5 years after the tolerance is established, modified,
or left in effect, demonstrating that the levels in food are not above
the levels anticipated. For the present action, EPA will issue such
data call-ins as are required by FFDCA section 408(b)(2)(E) and
authorized under FFDCA section 408(f)(1). Data will be required to be
submitted no later than 5 years from the date of issuance of these
tolerances.
Section 408(b)(2)(F) of FFDCA states that the Agency may use data
on the actual percent of food treated for assessing chronic dietary
risk only if:
Condition a: The data used are reliable and provide a
valid basis to show what percentage of the food derived from such crop
is likely to contain the pesticide residue.
Condition b: The exposure estimate does not underestimate
exposure for any significant subpopulation group.
Condition c: Data are available on pesticide use and food
consumption in a particular area, the exposure estimate does not
understate exposure for the population in such area.
In addition, the Agency must provide for periodic evaluation of any
estimates used. To provide for the periodic evaluation of the estimate
of PCT as required by FFDCA section 408(b)(2)(F), EPA may require
registrants to submit data on PCT.
For the acute assessment, the Agency estimated the PCT for existing
uses as follows:
Soybeans, 2.5%; wheat, 2.5%.
For the chronic assessment, the Agency estimated the PCT for
existing uses as follows:
Soybeans, 1%; wheat, 1%.
In most cases, EPA uses available data from United States
Department of Agriculture/National Agricultural Statistics Service
(USDA/NASS), proprietary market surveys, and the National Pesticide Use
Database for the chemical/crop combination for the most recent 6-7
years. EPA uses an average PCT for chronic dietary risk analysis. The
average PCT figure for each existing use is derived by combining
available public and private market survey data for that use, averaging
across all observations, and rounding to the nearest 5%, except for
those situations in which the average PCT is less than one. In those
cases, 1% is used as the average PCT and 2.5% is used as the maximum
PCT. EPA uses a maximum PCT for acute dietary risk analysis. The
maximum PCT figure is the highest observed maximum value reported
within the recent 6 years of available public and private market survey
data for the existing use and rounded up to the nearest multiple of 5%.
The Agency believes that the three conditions discussed in Unit
III.C.1.iv. have been met. With respect to Condition a, PCT estimates
are derived from Federal and private market survey data, which are
reliable and have a valid basis. The Agency is reasonably certain that
the percentage of the food treated is not likely to be an
underestimation. As to Conditions b and c, regional consumption
information and consumption information for significant subpopulations
is taken into account through EPA's computer-based model for evaluating
the exposure of significant subpopulations including several regional
groups. Use of this consumption information in EPA's risk assessment
process ensures that EPA's exposure estimate does not understate
exposure for any significant subpopulation group and allows the Agency
to be reasonably certain that no regional population is exposed to
residue levels higher than those estimated by the Agency. Other than
the data available through national food consumption surveys, EPA does
not have available reliable information on the regional consumption of
food to which thiabendazole may be applied in a particular area.
2. Dietary exposure from drinking water. The Agency used screening
level water exposure models in the dietary exposure analysis and risk
assessment for thiabendazole in drinking water. These simulation models
take into account data on the physical, chemical, and fate/transport
characteristics of thiabendazole. Further information regarding EPA
drinking water models used in pesticide exposure assessment can be
found at https://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/about-water-exposure-models-used-pesticide.
Based on the FQPA Index Reservoir Screening Tool (FIRST) and
Pesticide Root Zone Model GroundWater (PRZM-GW), the estimated drinking
water concentrations (EDWCs) of thiabendazole for acute exposures are
estimated to be 3.80 parts per billion (ppb) for surface water and 0.62
ppb for ground water, and for chronic exposures are estimated to be
0.47 ppb for surface water.
Modeled estimates of drinking water concentrations were directly
entered into the dietary exposure model. For the acute dietary risk
assessment, the water concentration value of 3.80 ppb was used to
assess the contribution to drinking water.
For the chronic dietary risk assessment, the water concentration of
value 0.47 ppb was used to assess the contribution to drinking water.
3. From non-dietary exposure. The term ``residential exposure'' is
used in this document to refer to non-occupational, non-dietary
exposure (e.g., for lawn and garden pest control, indoor pest control,
termiticides, and flea and tick control on pets).
Thiabendazole is currently registered for use as antimicrobial
ingredient in paint, sponges, carpet backing, canvas textiles,
wallboard and ceiling tiles, polyurethane foam, plastics and rubber,
paper, and coatings and filters used in HVAC systems. There are two
antimicrobial exposure scenarios that were assessed for residential
exposures which are expected to result in the highest exposures from
these antimicrobial uses: Treated paint and impregnated sponges. The
other antimicrobial uses of thiabendazole (carpet backing, canvas
textiles, wallboard and ceiling tiles, polyurethane foam, plastics and
rubber, paper, and coatings and filters used in HVAC systems) are not
expected to cause exposure in residential settings because there is no
direct contact to the treated articles, the vapor pressure of
thiabendazole is very low, and the unlikelihood that the treated
plastics and rubbers would be used in toys.
EPA assessed residential exposure to treated paint and impregnated
sponges using the following assumptions: For treated paint, residential
short-term dermal and inhalation exposure to residential handlers using
brush/roller application and airless sprayer application; for the
impregnated sponge use, short- and intermediate-term incidental oral
exposure. Thiabendazole treated sponges are limited to 600 ppm
thiabendazole on a sponge. Various residue amounts may be transferred
from the sponge to food contact surfaces, such as countertops and
utensils/glassware, and then to food and subsequently ingested. An
assessment was conducted for incidental oral exposure assuming that
100% of the thiabendazole on a treated sponge is transferred to
surfaces over 20 days and that each 20 days the user would use a new
sponge (5% released per day). This assumption is considered
conservative because (1) sponges will generally be used much longer
than 20 days; (2) it is unlikely that 100% of the thiabendazole would
be released from the sponge in
[[Page 65293]]
such a short period; and (3) it is very unlikely that 100% of any
released thiabendazole would be transferred to countertops because this
assumption does not account any thiabendazole that is washed down the
sink or that normally degrades.
Further information regarding EPA standard assumptions and generic
inputs for residential exposures may be found at https://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/standard-operating-procedures-residential-pesticide.
4. Cumulative effects from substances with a common mechanism of
toxicity. Section 408(b)(2)(D)(v) of FFDCA requires that, when
considering whether to establish, modify, or revoke a tolerance, the
Agency consider ``available information'' concerning the cumulative
effects of a particular pesticide's residues and ``other substances
that have a common mechanism of toxicity.''
EPA has not found thiabendazole to share a common mechanism of
toxicity with any other substances, and thiabendazole does not appear
to produce a toxic metabolite produced by other substances. For the
purposes of this tolerance action, therefore, EPA has assumed that
thiabendazole does not have a common mechanism of toxicity with other
substances. For information regarding EPA's efforts to determine which
chemicals have a common mechanism of toxicity and to evaluate the
cumulative effects of such chemicals, see EPA's Web site at https://www2.epa.gov/pesticide-science-and-assessing-pesticide-risks/cumulative-assessment-risk-pesticides.
D. Safety Factor for Infants and Children
1. In general. Section 408(b)(2)(C) of FFDCA provides that EPA
shall apply an additional tenfold (10X) margin of safety for infants
and children in the case of threshold effects to account for prenatal
and postnatal toxicity and the completeness of the database on toxicity
and exposure unless EPA determines based on reliable data that a
different margin of safety will be safe for infants and children. This
additional margin of safety is commonly referred to as the Food Quality
Protection Act Safety Factor (FQPA SF). In applying this provision, EPA
either retains the default value of 10X, or uses a different additional
safety factor when reliable data available to EPA support the choice of
a different factor.
2. Prenatal and postnatal sensitivity. No evidence of increased
quantitative or qualitative susceptibility was seen following in utero
exposure to thiabendazole with rats or rabbits in the prenatal
developmental studies or in young rats in the 2-generation reproduction
study. There is no evidence for neurotoxicity following oral exposures
to thiabendazole. Thyroid toxicity was seen following subchronic and
chronic exposures to adult rats in multiple studies. There is, however,
no data regarding the potential effects of thiabendazole on thyroid
homeostasis in the young animals. This lack of characterization creates
uncertainty with regards to potential life stage sensitivities due to
exposure to thiabendazole. Therefore, the Agency is requiring a
developmental thyroid assay in rats with thiabendazole. This study will
better address the concern for potential thyroid toxicity in the young.
3. Conclusion. EPA has determined that reliable data show the
safety of infants and children would be adequately protected if the
FQPA SF is retained at 10X in the form of a database uncertainty factor
(UFDB). That decision is based on the following findings:
i. The toxicology database for thiabendazole is complete with the
exception of a developmental thyroid toxicity study. Based on a WOE
approach considering all the available hazard and exposure information
for thiabendazole, the Agency concluded that a developmental thyroid
toxicity study is required since there is clear evidence of thyroid
toxicity in adult animals and thus a concern for potential toxicity
during pregnancy, infancy and childhood. The developmental thyroid
toxicity study will better address this concern than a developmental
neurotoxicity study. Acceptable studies are available for
developmental, reproduction, chronic, subchronic, subchronic
neurotoxicity and immunotoxicity.
ii. There is no indication that thiabendazole is a neurotoxic
chemical and there is no need for a developmental neurotoxicity study
or additional UFs to account for neurotoxicity.
iii. The data submitted to the Agency, as well as those from
published literature, demonstrate no increased susceptibility in rats,
rabbits, or mice to in utero and/or early postnatal exposure to
thiabendazole. In the prenatal developmental toxicity studies in rats,
rabbits, and mice and in the 2-generations reproduction study in rats,
developmental effects in the fetuses or neonates occurred at or above
doses that caused maternal or parental toxicity. A developmental
neurotoxicity study with thiabendazole was deemed not required by the
Agency.
There is evidence of thyroid toxicity following subchronic and
chronic exposures to rats characterized as histopathological changes in
the thyroid in multiple studies in rats. Disruption of thyroid
homeostasis is the initial, critical effect that may lead to adverse
effects on the developing nervous system. Thus, as noted above, a
developmental thyroid study is required.
iv. There are no residual uncertainties in the exposure database.
The dietary risk assessment is conservative and will not underestimate
dietary and/or non-dietary occupational exposure to thiabendazole. The
acute and chronic dietary assessments conducted with the Dietary
Exposure Evaluation Model software with the Food Commodity Intake
Database (DEEM-FCID) were refined analyses. The assessments utilized
anticipated residues, default processing factors, and available percent
crop treated data. The DEEM analysis also used Tier 1 drinking water
estimates. For these reasons it can be concluded that the DEEM-FCID
analysis does not underestimate risk from acute or chronic exposure to
thiabendazole. Similarly, EPA does not believe that the non-dietary
occupational exposures are underestimated because they are also based
on conservative assumptions, including maximum application rates, and
standard values for unit exposures and acreage treated/amount handled.
These assessments will not underestimate the exposure and risks posed
by thiabendazole.
E. Aggregate Risks and Determination of Safety
EPA determines whether acute and chronic dietary pesticide
exposures are safe by comparing aggregate exposure estimates to the
acute PAD (aPAD) and chronic PAD (cPAD). For linear cancer risks, EPA
calculates the lifetime probability of acquiring cancer given the
estimated aggregate exposure. Short-, intermediate-, and chronic-term
risks are evaluated by comparing the estimated aggregate food, water,
and residential exposure to the appropriate PODs to ensure that an
adequate MOE exists.
1. Acute risk. Using the exposure assumptions discussed in this
unit for acute exposure, the acute dietary exposure from food and water
to thiabendazole at the 99.9th percentile of exposure will occupy 68%
of the aPAD for children 1-2 years old, the population group receiving
the greatest exposure.
2. Chronic risk. Using the exposure assumptions described in this
unit for chronic exposure, EPA has concluded
[[Page 65294]]
that chronic exposure to thiabendazole from food and water will utilize
5.1% of the cPAD for children 1-2 years old, the population group
receiving the greatest exposure. Based on the explanation in Unit
III.C.3., regarding residential use patterns, chronic residential
exposure to residues of thiabendazole is not expected.
3. Short- and intermediate-term risk. Short- and intermediate-term
aggregate exposure takes into account short- and intermediate-term
residential exposure plus chronic exposure to food and water
(considered to be a background exposure level).
Thiabendazole is currently registered for uses that could result in
short- and intermediate-term residential exposure, and the Agency has
determined that it is appropriate to aggregate chronic exposure through
food and water with short- and intermediate-term residential exposures
to thiabendazole.
Using the exposure assumptions described in this unit for short-
and intermediate-term exposures, EPA has concluded the combined short-
and intermediate-term food, water, and residential exposures result in
aggregate MOEs from the paint use of 2,000 or greater for all
population subgroups and aggregate MOEs from the sponge use of 1,400
for children 1-2 years old and 7,000 for the general population.
Because EPA's level of concern for thiabendazole is a MOE of 300 or
below, these MOEs are not of concern.
4. Aggregate cancer risk for U.S. population. As discussed in Unit
III.A., EPA is regulating chronic dietary risk, including cancer risk,
with a chronic RfD that reflects a dose level below those levels at
which thyroid hormone balance is impacted, which is protective of
potential carcinogenic effects. Based on the lack of chronic risk, EPA
concludes there is not a cancer risk from exposure to thiabendazole.
5. Determination of safety. Based on these risk assessments, EPA
concludes that there is a reasonable certainty that no harm will result
to the general population, or to infants and children from aggregate
exposure to thiabendazole residues.
IV. Other Considerations
A. Analytical Enforcement Methodology
Acceptable enforcement analytical methods are available for
thiabendazole and benzimidazole in plant commodities. Four
spectrophotofluorometric methods for the determination of thiabendazole
are published in the Pesticide Analytical Manual (PAM) Vol. II, and a
high performance liquid chromatography (HPLC) method with fluorescence
detection (FLD) for the determination of benzimidazole (free and
conjugated) is identified in the U.S. EPA Index of Residue Analytical
Methods under thiabendazole as Study No. 93020.
Another adequate analytical method, GRM040.05A, is also available
for data collection and tolerance enforcement of residues of
thiabendazole and benzimidazole (free and conjugated) in/on plant
commodities. Method GRM040.05A, developed by Syngenta Crop Protection,
LLC, is a high performance liquid chromatography with tandem mass
spectrometry detection (LC/MS/MS) method used for data collection in
crop matrices. HED has designated Method GRM040.05A as a new tolerance
enforcement method.
Both methods may be requested from: Chief, Analytical Chemistry
Branch, Environmental Science Center, 701 Mapes Rd., Ft. Meade, MD
20755-5350; telephone number: (410) 305-2905; email address:
residuemethods@epa.gov.
B. International Residue Limits
In making its tolerance decisions, EPA seeks to harmonize U.S.
tolerances with international standards whenever possible, consistent
with U.S. food safety standards and agricultural practices. EPA
considers the international maximum residue limits (MRLs) established
by the Codex Alimentarius Commission (Codex), as required by FFDCA
section 408(b)(4). The Codex Alimentarius is a joint United Nations
Food and Agriculture Organization/World Health Organization food
standards program, and it is recognized as an international food safety
standards-setting organization in trade agreements to which the United
States is a party. EPA may establish a tolerance that is different from
a Codex MRL; however, FFDCA section 408(b)(4) requires that EPA explain
the reasons for departing from the Codex level.
The Codex has not established a MRL for thiabendazole on any of the
commodities cited in this document.
C. Response to Comments
A comment was submitted by the Center for Food Safety and was
primarily concerned about EPA's consideration of the impacts of
thiabendazole on the environment, pollinators, and endangered species.
This comment is not relevant to the Agency's evaluation of safety of
the thiabendazole tolerances under section 408 of the FFDCA, which
requires the Agency to evaluate the potential harms to human health,
not effects on the environment.
D. Revisions to Petitioned-For Tolerances
The petitioned-for tolerances did not include measurement of
benzimidazole (free and conjugated) which is a residue of concern for
regulatory purposes. Therefore, the petitioned-for tolerance for the
vegetable, legume, group 6 at 0.01 ppm for thiabendazole only, is
adjusted to 0.02 ppm to account for the combined residues of
thiabendazole and benzimidazole (free and conjugated). Also, EPA
concluded that the maximum levels of the combined residues of concern
in/on the representative crop commodities of vegetable, foliage of
legume, group 7 are within 5x, and that a crop group 7 tolerance level
of 0.20 ppm is more appropriate than the petitioned-for separate
tolerances for pea, field, hay; pea, field, vines; and vegetable,
foliage of legume, group 7, except pea, field, hay and vines.
E. International Trade Considerations
In this rulemaking, EPA is adding an expiration date of March 21,
2017 to the existing tolerances for bean, dry, seed at 0.1 ppm and
soybean at 0.1 ppm. These tolerances were based on foliar uses of
thiabendazole which are no longer registered and Syngenta requested
that these tolerances be removed as part of the petition and notice of
filing (NOF). The seed treatment uses on dry bean seed and soybean is
now covered by the tolerance being established on vegetable, legume,
group 6 at 0.02 ppm. This new tolerance is lower than some existing
MRLs on these commodities in Europe and other countries.
In accordance with the World Trade Organization's (WTO) Sanitary
and Phytosanitary Measures Agreement, EPA notified the WTO of the
request to revise these tolerances on September 9, 2015, as WTO
notification G/SPS/N/USA/2779. In this action, EPA is allowing the
existing higher tolerances to remain in effect for 6 months following
the publication of this rule in order to allow a reasonable interval
for producers in exporting countries to adapt to the requirements of
these modified tolerances. On March 21, 2017, those existing higher
tolerances will expire, and the new reduced tolerances for vegetable,
legume, group 6 at 0.02 ppm will remain to cover residues of
thiabendazole on those commodities. Before that date, residues of
thiabendazole on those commodities would be permitted up to the higher
tolerance levels; after that date, residues of thiabendazole on
vegetable, legume, group 6 will need to comply with the
[[Page 65295]]
new lower tolerance levels. This reduction in tolerance is not
discriminatory; the same food safety standard contained in the FFDCA
applies equally to domestically produced and imported foods.
V. Conclusion
Therefore, tolerances are established for residues of thiabendazole
in or on vegetable, foliage of legume, group 7 at 0.20 ppm and
vegetable, legume, group 6 at 0.02 ppm. The Agency is also adding an
expiration date of March 21, 2017 to the existing tolerances for bean,
dry, seed at 0.1 ppm and soybean at 0.1 ppm. Residues of thiabendazole
will be covered by these higher tolerances until the expiration date,
after which time, they will need to comply with the lower tolerance
being established today on the vegetable, legume, group 6 at 0.02 ppm.
The tolerance for group 6 without a time limitation supersedes the
existing section 18 time-limited tolerance for ``pea, succulent
shelled''; therefore, the Agency is removing that section 18 tolerance.
The Agency is also removing the threshold of regulation
determination for thiabendazole from 180.2010 because it is no longer
necessary. Lastly, this regulation additionally establishes a time-
limited tolerances for residues of thiabendazole in or on sweet potato
at 10 ppm.
VI. Statutory and Executive Order Reviews
This action establishes tolerances under FFDCA section 408(d) in
response to a petition submitted to the Agency. The Office of
Management and Budget (OMB) has exempted these types of actions from
review under Executive Order 12866, entitled ``Regulatory Planning and
Review'' (58 FR 51735, October 4, 1993). Because this action has been
exempted from review under Executive Order 12866, this action is not
subject to Executive Order 13211, entitled ``Actions Concerning
Regulations That Significantly Affect Energy Supply, Distribution, or
Use'' (66 FR 28355, May 22, 2001) or Executive Order 13045, entitled
``Protection of Children from Environmental Health Risks and Safety
Risks'' (62 FR 19885, April 23, 1997). This action does not contain any
information collections subject to OMB approval under the Paperwork
Reduction Act (PRA) (44 U.S.C. 3501 et seq.), nor does it require any
special considerations under Executive Order 12898, entitled ``Federal
Actions to Address Environmental Justice in Minority Populations and
Low-Income Populations'' (59 FR 7629, February 16, 1994).
Since tolerances and exemptions that are established on the basis
of a petition under FFDCA section 408(d), such as the tolerance in this
final rule, do not require the issuance of a proposed rule, the
requirements of the Regulatory Flexibility Act (RFA) (5 U.S.C. 601 et
seq.), do not apply.
This action directly regulates growers, food processors, food
handlers, and food retailers, not States or tribes, nor does this
action alter the relationships or distribution of power and
responsibilities established by Congress in the preemption provisions
of FFDCA section 408(n)(4). As such, the Agency has determined that
this action will not have a substantial direct effect on States or
tribal governments, on the relationship between the national government
and the States or tribal governments, or on the distribution of power
and responsibilities among the various levels of government or between
the Federal Government and Indian tribes. Thus, the Agency has
determined that Executive Order 13132, entitled ``Federalism'' (64 FR
43255, August 10, 1999) and Executive Order 13175, entitled
``Consultation and Coordination with Indian Tribal Governments'' (65 FR
67249, November 9, 2000) do not apply to this action. In addition, this
action does not impose any enforceable duty or contain any unfunded
mandate as described under Title II of the Unfunded Mandates Reform Act
(UMRA) (2 U.S.C. 1501 et seq.).
This action does not involve any technical standards that would
require Agency consideration of voluntary consensus standards pursuant
to section 12(d) of the National Technology Transfer and Advancement
Act (NTTAA) (15 U.S.C. 272 note).
VII. Congressional Review Act
Pursuant to the Congressional Review Act (5 U.S.C. 801 et seq.),
EPA will submit a report containing this rule and other required
information to the U.S. Senate, the U.S. House of Representatives, and
the Comptroller General of the United States prior to publication of
the rule in the Federal Register. This action is not a ``major rule''
as defined by 5 U.S.C. 804(2).
List of Subjects in 40 CFR Part 180
Environmental protection, Administrative practice and procedure,
Agricultural commodities, Pesticides and pests, Reporting and
recordkeeping requirements.
Dated: August 26, 2016.
Michael Goodis,
Acting Director, Registration Division, Office of Pesticide Programs.
Therefore, 40 CFR chapter I is amended as follows:
PART 180--[AMENDED]
0
1. The authority citation for part 180 continues to read as follows:
Authority: 21 U.S.C. 321(q), 346a and 371.
0
2. In Sec. 180.242;
0
a. Revise the entries ``bean, dry, seed'' and ``soybean'' to the table
in paragraph (a)(1);
0
b. Add alphabetically the entries ``Vegetable, foliage of legume, group
7'' and ``Vegetable, legume, group 6'' to the table in paragraph (a)(1)
0
c. Remove the entry for ``Pea, succulent shelled'' from the table in
paragraph (b);
0
d. Add alphabetically the entry ``sweet potato'' to the table in
paragraph (b).
The additions and revisions read as follows:
Sec. 180.242 Thiabendazole; tolerances for residues.
(a) * * *
(1) * * *
------------------------------------------------------------------------
Parts per
Commodity million
------------------------------------------------------------------------
* * * * *
Bean, dry, seed \2\..................................... 0.1
* * * * *
Soybean \2\............................................. 0.1
* * * * *
Vegetable, foliage of legume, group 7................... 0.20
Vegetable, legume, group 6.............................. 0.02
* * * * *
------------------------------------------------------------------------
\2\ This tolerance expires on March 21, 2017.
(b) * * *
------------------------------------------------------------------------
Parts per
Commodity million Expiration date
------------------------------------------------------------------------
Sweet potato..................... 10 December 31, 2019.
------------------------------------------------------------------------
[[Page 65296]]
* * * * *
Sec. 180.2010 [Removed and Reserved]
0
3. Section 180.2010 is removed and reserved.
[FR Doc. 2016-21753 Filed 9-21-16; 8:45 am]
BILLING CODE 6560-50-P